Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.22.2.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 22,676,000 $ 77,404,000
Accounts receivable - trade 1,000,000 426,000
Settlement receivable - current portion 5,100,000 5,100,000
Investments in debt securities 10,845,000 19,570,000
Inventory 3,900,000 27,000
Prepaid expenses and other current assets 1,549,000 2,070,000
Total Current Assets 45,070,000 104,597,000
Restricted cash 5,996,000 0
Convertible promissory note receivable and accrued interest 1,631,000 1,556,000
Settlement receivable - noncurrent portion   5,100,000
Finance lease right-of-use assets, net of accumulated amortization 74,000 26,111,000
Operating lease right-of-use asset 5,020,000  
Fixed assets, net of accumulated depreciation 36,661,000 8,628,000
Intangible assets, net of accumulated amortization 4,851,000 952,000
Prepaid expenses - noncurrent 74,000  
Security deposits 29,000 24,000
Total Assets 99,406,000 146,968,000
Current liabilities:    
Accounts payable 4,264,000 2,254,000
Accrued expenses (related party of $0 and $701 as of June 30, 2022 and 2021, respectively) 3,764,000 3,001,000
Finance lease obligations - current portion 46,000 367,000
Operating lease obligation - current portion 101,000  
Note payable - PPP loan - current portion   600,000
Term note payable - net of deferred financing costs 22,161,000 600,000
Contract liabilities 100,000 423,000
Total Current Liabilities 30,436,000 6,645,000
Finance lease obligations - net of current portion 30,000 31,755,000
Operating lease obligation - net of current portion 5,455,000  
Total Liabilities 35,921,000 38,400,000
iBio, Inc. Stockholders' Equity:    
Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 1,000 and 0 shares issued and outstanding as of June 30, 2022 and 2021, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2022, and June 30, 2021; 8,727,158 and 8,714,924 shares issued and outstanding as of June 30, 2022 and 2021, respectively 9,000 9,000
Additional paid-in capital 287,619,000 282,266,000
Accumulated other comprehensive loss (213,000) (63,000)
Accumulated deficit (223,930,000) (173,627,000)
Total iBio, Inc. Stockholders' Equity 63,485,000 108,585,000
Noncontrolling interest   (17,000)
Total Equity 63,485,000 108,568,000
Total Liabilities and Equity $ 99,406,000 $ 146,968,000